What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
The phase 3 EASE SBS 1 trial showed a statistically significant reduction in parenteral support volume with twice-weekly glepaglutide compared to placebo. However, FDA identified significant uncertainties in the trial’s conduct, including protocol deviations and missing data, which weaken the reliability of the efficacy results.
Does the economic case hold at the expected price? — Cost effectiveness
No cost-utility model, ICER, or economic analysis was identified for glepaglutide. Therefore, cost-effectiveness cannot be assessed.
Is there quality-of-life evidence payers weigh? — Quality of life
The PGIC showed significant benefits, but FDA found it inadequate as the sole anchor for meaningful-change analysis. No validated HRQoL instruments or utility values were reported, limiting the assessment of HRQoL impact.
Does the safety profile hold up for payers? — Safety and Adverse Effects
Short-term safety data showed common GLP-2 class-related adverse events. However, FDA inspection found underreporting of adverse events, and long-term safety data are limited, reducing confidence in the safety profile.
Was the drug compared against what payers expect? — Comparator Selection
The trial used placebo as a comparator, which is appropriate for detecting pharmacological benefit but not for assessing comparative value against established treatments like teduglutide.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial population was representative of a high-burden SBS-IF subset, but lacked diversity in terms of race and ethnicity. Subgroup analyses were limited by small sample sizes.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Glepaglutide administration is intended to be straightforward with a prefilled pen, but no data on training requirements or implementation advantages were provided.
Are the wider system costs understood? — Resource Use and Cost Implications
No budget-impact or resource-use data were presented, making it impossible to assess the resource implications of glepaglutide.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The trial had strengths in design but significant methodological weaknesses, including protocol deviations and missing data, which lower confidence in the evidence quality.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
High uncertainty remains due to issues with endpoint execution, long-term durability, and safety. No formal sensitivity analysis was conducted. [Expert decision MG: grade set to B++ — Corresponding to the development phase]
